Esposito, Anthony J.
Bhatraju, Pavan K.
Stapleton, Renee D.
Wurfel, Mark M.
Mikacenic, Carmen
Funding for this research was provided by:
National Institutes of Health (K23HL120896)
Parker B. Francis Fellowship
National Institutes of Health (K23HL105654)
National Institutes of Health (P50HL073996)
National Institutes of Health (F32DK112532)
University of Washington
Article History
Received: 3 July 2017
Accepted: 23 November 2017
First Online: 14 December 2017
Authors’ information
: None.
: The human samples used in this study were originally obtained for “A Phase II Randomized Placebo-Controlled Trial of Omega-3 Fatty Acids for the Treatment of Acute Lung Injury” by Stapleton et al. [CitationRef removed]. Written informed consent was obtained from legal next of kin for all subjects. Human Subjects Committees of this multicenter trial approved the study at the following institutions and locations: University of Washington in Seattle, Washington; St. Michael’s Hospital in Toronto, Ontario; St. Alphonsus Medical Center in Boise, Idaho; and Fletcher Allen Health Care in Burlington, Vermont). The Data Safety Monitoring Board (DSMB) monitored the trial, which was registered as NCT00351533.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.